Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
9 pending office actions • 6 clients • 8 examiners • 3 art units • 0 of 9 (0%) have an AI response strategy ready
Antheros Legal Advisors LLP operates in the Biotechnology & Pharmaceuticals technology area, with 170 career applications. This boutique scale suggests a concentrated focus on life sciences innovations and specialized client needs. The firm currently manages 7 pending office actions on its docket, representing its active prosecution workload.
The firm's resolved allowance rate pct stands at 69.77, reflecting the inherent challenges of prosecution in the biotechnology sector. Prosecution typically involves an avg office actions per allowance of 2.67. This average suggests that the firm generally reaches an allowance within several substantive exchanges with the USPTO examiner, which is a standard pace for this field.
Practitioners can look to the 69.77 resolved allowance rate pct as a measure of the firm's performance in a technically demanding field. The 2.67 avg office actions per allowance provides a benchmark for the expected prosecution cycle. With 170 career applications and 7 pending office actions, the firm maintains a consistent presence in the biotechnology patent space for its clients.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §112 only | 1 (11%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 4 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CASLER, BRIAN L | 2 | 78.8% | +22.2% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.8% | +30.2% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| SHIM, MORGAN SANGJO | 1 | 0.0% | +0.0% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| BORI, IBRAHIM D | 1 | 43.8% | +38.9% |
| HOFFA, ANGELA MARIE | 1 | 67.6% | +28.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18888376 | Substituted Amine Compounds, Compositions and Methods of Use | HASTINGS, ALISON AZAR | — |
| 18638206 | REMOTE DRIVE TECHNIQUES FOR MAGNETIC FIELD THERAPY | CASLER, BRIAN L | — |
| 18638197 | TRANSCRANIAL MAGNETIC STIMULATION USING ROTATING FIELD VECTORS | CASLER, BRIAN L | — |
| 18418108 | HANDHELD ELECTROENCEPHALOGRAPHY DEVICE | SHIM, MORGAN SANGJO | — |
| 18415494 | NANOPARTICLES AND METHODS OF USE | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18447040 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF | BORI, IBRAHIM D | 52d overdue |
| 18888376 | Substituted Amine Compounds, Compositions and Methods of Use | HASTINGS, ALISON AZAR | — |
| 18818418 | HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF | ALSOMAIRY, SARAH ABDOALATIF | — |
| 18664161 | CLAUDIN 18.2 T CELL-ANTIGEN COUPLERS AND USES THEREOF | SZPERKA, MICHAEL EDWARD | — |
| 18638206 | REMOTE DRIVE TECHNIQUES FOR MAGNETIC FIELD THERAPY | CASLER, BRIAN L | — |
| 18638197 | TRANSCRANIAL MAGNETIC STIMULATION USING ROTATING FIELD VECTORS | CASLER, BRIAN L | — |
| 18415494 | NANOPARTICLES AND METHODS OF USE | VARADARAJ, ARCHANA | — |
| 18298306 | SYSTEMS AND METHODS FOR PROVIDING ALPHA BURST BRAIN STIMULATION | HOFFA, ANGELA MARIE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| WAVE NEUROSCIENCE, INC. | 4 |
| Deep Apple Therapeutics, Inc. | 1 |
| Nectin Therapeutics Ltd. | 1 |
| Triumvira Immunologics Usa, Inc. | 1 |
| Qana Therapeutics Inc. | 1 |
| Tvardi Operating Company, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 3791 | 1 |
| 1629 | 1 |
| 3799 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18888376 | Substituted Amine Compounds, Compositions and Methods of Use | Deep Apple Therapeutics, Inc. | HASTINGS, ALISON AZAR | §102§112 | Non-Final OA | — | Pending | Sep 18, 2024 | |
| 18818418 | HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF | Nectin Therapeutics Ltd. | ALSOMAIRY, SARAH ABDOALATIF | §112DP | Non-Final OA | — | Pending | Aug 28, 2024 | |
| 18664161 | CLAUDIN 18.2 T CELL-ANTIGEN COUPLERS AND USES THEREOF | Triumvira Immunologics Usa, Inc. | SZPERKA, MICHAEL EDWARD | DP | Non-Final OA | — | Pending | May 14, 2024 | |
| 18638206 | REMOTE DRIVE TECHNIQUES FOR MAGNETIC FIELD THERAPY | Wave Neuroscience, Inc. | CASLER, BRIAN L | §102§103 | Non-Final OA | — | Pending | Apr 17, 2024 | |
| 18638197 | TRANSCRANIAL MAGNETIC STIMULATION USING ROTATING FIELD VECTORS | Wave Neuroscience, Inc. | CASLER, BRIAN L | §102§103§112 | Non-Final OA | — | Pending | Apr 17, 2024 | |
| 18418108 | HANDHELD ELECTROENCEPHALOGRAPHY DEVICE | Wave Neuroscience, Inc. | SHIM, MORGAN SANGJO | 3791 | §103 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18415494 | NANOPARTICLES AND METHODS OF USE | Qana Therapeutics Inc. | VARADARAJ, ARCHANA | §102§103 | Non-Final OA | — | Pending | Jan 17, 2024 | |
| 18447040 | THERAPEUTIC COMPOUNDS, FORMULATIONS, AND USE THEREOF | Tvardi Operating Company, Inc. | BORI, IBRAHIM D | 1629 | §103§112DP | Final Rejection | 52d overdue | Pending | Aug 09, 2023 |
| 18298306 | SYSTEMS AND METHODS FOR PROVIDING ALPHA BURST BRAIN STIMULATION | Wave Neuroscience, Inc. | HOFFA, ANGELA MARIE | 3799 | §112 | Non-Final OA | — | Pending | Apr 10, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial